Volta Medical Appoints Bill Hoffman as Executive Chairman to Enhance AI Solutions

Volta Medical Welcomes Bill Hoffman as Executive Chairman

Volta Medical, a groundbreaking entity in healthcare technology, has announced the appointment of Bill Hoffman as the Executive Chairman of its Board of Directors on April 8, 2025. This strategic move is poised to bolster the company’s mission in enhancing cardiac care through Artificial Intelligence (AI).

Bill Hoffman, with his extensive experience and a stellar track record, is recognized for his leadership in propelling innovative startups to success. Formerly the CEO of Inari Medical, Hoffman played an instrumental role in the company's transformation from an early-stage concept to a publically-traded entity achieving over $500 million in revenue and making a substantial impact in treating venous thromboembolism. In February 2025, Inari was acquired by Stryker for a remarkable $4.9 billion, further solidifying Hoffman's reputation in the industry.

The absence of quality care for arrhythmia patients and the burgeoning demand for advanced treatment methodologies make Hoffman’s expertise especially relevant. According to Théophile Mohr-Durdez, CEO and co-founder of Volta Medical, “We are honored to welcome Bill Hoffman as our Executive Chairman. His extensive experience in the development, commercialization, and scaling of novel medical technologies will be invaluable as we accelerate global access to our AI-based solutions for cardiac ablation.”

Hoffman expressed his enthusiasm for joining Volta, emphasizing the company's breakthrough technology that has, for the first time in ablation history, significantly improved clinical outcomes for patients with atrial fibrillation (AF). “Volta’s technology offers a clinically significant enhancement in efficacy for patients suffering from AF. I am excited to join the Volta team and contribute to our shared goal of making a meaningful impact on patients' lives,” said Hoffman.

In addition to Hoffman's appointment, Jerome Kalifa, MD, has been designated as Executive Vice President. Dr. Kalifa will continue his role as Chief Medical Officer, further ensuring a seamless leadership transition at Volta. He commented on the shared mission with Hoffman, stating, “We are excited to work with Bill on this mission to eliminate atrial fibrillation by treating as many patients as possible, as quickly as possible.”

This executive shift aligns with the recent publication of the TAILORED-AF clinical trial in Nature Medicine, showcasing that an AI-guided procedure using Volta’s technology combined with conventional pulmonary vein isolation (PVI) has significantly outperformed PVI alone in enhancing patient outcomes with persistent atrial fibrillation.

Understanding Atrial Fibrillation

Atrial fibrillation (AF) is recognized by the American Heart Association (AHA) as an irregular heart rhythm that can lead to complications such as blood clots, strokes, heart failure, and other cardiac issues. Globally, approximately 33 million individuals live with AF, and untreated AF can double the risk of heart-related deaths, posing a five-fold increase in stroke risk. Alarmingly, only an estimated 15% of the 2.5 million eligible AF patients in the U.S. receive catheter ablation treatment.

The Mission of Volta Medical

Founded in 2016 in Marseille by a group comprising three physicians and a data specialist, Volta Medical is a health tech firm dedicated to developing AI-driven software solutions aimed at assisting electrophysiologists during arrhythmia treatment procedures, ultimately enhancing clinical outcomes for patients. Their flagship product, the Volta AF-Xplorer™, serves as a real-time AI digital companion that aids cardiologists in identifying specific abnormal electrograms during AF procedures.

The Volta AF-Xplorer™ has been validated for versatility, demonstrated efficacy with several leading AF identification and recording systems, and has received both FDA 510(k) clearance and CE marking. Volta Medical has also initiated the “AI for Persistent AF Care” awareness program designed to educate underserved atrial fibrillation patients about available therapy options.

For further information, visit Volta Medical's website.

Press Contact:
Molly Megna
Senior Marketing Manager
Volta Medical
Email: [email protected]